Radiopharm Theranostics announced positive imaging data has been published regarding its HER2 nanobody (RAD201) in the European Journal of Nuclear Medicine & Molecular Imaging. The publication indicated that RAD201 has a favourable biodistribution and showed high accumulation in all active HER2 positive tumor sites. It demonstrated a high target-to-background ratio, favourable tumor targeting and rapid blood clearance.

The publication also supports previous data regarding the safety profile for use of RAD201 in humans. In conclusion, the publication highlighted that RAD201 is a `promising non-invasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment'. This is made possible due to RAD201's ability to bind to a different part of the HER2 receptor.